In a blistering editorial in Science magazine, editor-in-chief Donald Kennedy notes that Pfizer has issued subpoenas to the New England Journal of Medicine in order to wade through confidential reviews of published studies of its Celebrex and Bextra painkillers, which are the subject of numerous product-liability lawsuits. As he sees it Pfizer wants it both ways - an opportunity to defend itself against litigation that involves dismissing the same confidential system that validates industry research. To Kennedy, it's a 'fishing expedition' that will undermine journal integrity.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments